		ICIVISE DISCLOSURE I O	IXIVI		
Date:		9/28/2022			
Your Name:		Yaakov Stern			
Manuscript Title:		Development, Initial Validation, and Ap [18F]MK-6240 Tau PET	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET		
Manuscript Number (if known):		TRCI-D-22-00086R1			
content of your manuscr affected by the content indicate a bias. If you are The author's relationship epidemiology of hyperte that medication is not m	ript. "Reli of the ma re in doub ps/activiti ension, yo nentioned t all suppo	ated" means any relation with for-profit or no inuscript. Disclosure represents a commitment of about whether to list a relationship/activity, dies/interests should be defined broadly. For each should declare all relationships with manufal in the manuscript.	/interest, it is preferable that you do so.		
		Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial planning	of the work		
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		al Institute on Aging	Click the tab key to add additional rows.		

this item. Time frame: past 36 months 2 Grants or \boxtimes None contracts from any entity (if not indicated in item #1 above). 3 Royalties or None licenses Columbia University licenses the Dependence Scale, and in accordance with university policy, Dr. Stern is entitled to royalties through this license

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None Eisai Lilly Arcadia	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Non	
6	Payment for expert testimony	None Non	
7	Support for attending meetings and/or travel	None Non	
8	Patents planned, issued or pending	None Non	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None Non	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	nse place an "X" next	t to th	e following statement to indicate your agreeme	nt:

Date:	9/28/2022
Your Name:	Joanna L. Shuping
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Cerv	None /eau Technologies	Full time Consultant of Enigma Biomedical Group which is the parent company of Cerveau Technologies who funded all work for this project and manuscript. Click the tab key to add additional rows.
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
		See above #1.	Paid to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	□ None Enigma Biomedical Group	Attending meetings and travel
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None Non	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None Cerveau Technologies	Stock, Options
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None ■	
	•	t to the following statement to indicate your agreeme	
\boxtimes	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.

Date:	9/29/2022
Your Name:	Dawn C. Matthews]
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.	
The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	ADM Diagnostics, Inc Cerveau Technologies, Inc./Enigma BioIntelligence	Salaried employee Contracted ADM Diagnostics to perform work Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None ■	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., in made to you or to your institution made to you or you or your institution made you have all you have all your institution made your institution made you have all your institution made you have your institution made your your your institution made you have your your your your your y	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None □	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	QIBA Tau PET Profile Committee Co-Chair Alzheimer's Drug Discovery Foundation Scientific Advisory Board member	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None ADM Diagnostics, Inc.	Employee stock/options
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None ■	
	-	t to the following statement to indicate your agreeme	
\boxtimes	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.

Date:	9/28/2022
Your Name:	Katarzyna Adamczuk
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	is
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/28/2022
Your Name:	David Scott
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Enig	Mone gma Biomedical Research	Clario effort on this project was funded by Enigma Click the tab key to add additional rows.
			Time frame: past 36 month	is .
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None ■	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None □	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None ■	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None □	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/28/2022
Your Name:	Christopher Rowe
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments made to you or to your institution)	
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	□ None Enigma	Grant to institution and provision of materials for
	funding, provision of study materials,	Cingina	MK6240 production
	medical writing,		Click the tab key to add additional rows.
	article processing charges, etc.) No time limit for this item.		
		Time frame: past 36 month	s
2	Grants or contracts from	□ None	
	any entity (if not	Eisai	Grant to institution
	indicated in item	Biogen	Grant to institution
	#1 above).	AbbVie	Grant to institution
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
		Prothena	Payment to me
5	Payment or honoraria for	□ None	
	lectures, presentations,	Biogen	Payment to me for preparation of educational materials
	speakers bureaus,		
	manuscript		
	writing or educational		
6	events Payment for	None	
	expert testimony	A Note	
7	Support for	□ None	
	attending meetings and/or travel	Cerveau Technology	Provided airfare and accommodation to attend
			MK6240 Users Meeting
8	Patents planned, issued or	None	
	pending		
9	Participation on	⊠ None	
9	a Data Safety	△ Notice	
	Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	□ None	
	other board,	Australian Dementia Network	Part time salary
	society, committee or		
	advocacy group, paid or unpaid		

			e all entities with whom you have this conship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/28/2022
Your Name:	William Charles Kreisl
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None grants R01AG063888, K23AG052633, and 021155 Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
		Cerveau Technologies	I received payments
		AbbVie Roche	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers		
	bureaus, manuscript writing or		
	educational events		
6	Payment for expert testimony	None ■	
-	C	N. N.	
7	attending	⊠ None	
	meetings and/or travel		
8	Patents planned,	None	
	issued or pending		
9	Participation on a Data Safety	None ■	
	Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	⊠ None	
	other board,		
	society, committee or		
	advocacy group, paid or unpaid		

ľ			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: Legal Control of the questions on this form.			

Date:	9/28/2022	
Your Name:	Sterling Johnson	
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET	
Manuscript Number (if known): TRCI-D-22-00086R1		
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.		
The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	□ None NIH R01AG027161, NIH R01AG021155	Grant to Institution Click the tab key to add additional rows.
	No time limit for this item.		
		Time frame: past 36 month	S
2	Grants or contracts from	□ None	
	any entity (if not indicated in item #1 above).	Cerveau Technologies	Grant to institution
3	Royalties or licenses	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None Roche Diagnostics Eisai Merck Prothena	Payment to Individual Payment to Individual Payment to Individual Payment to Individual
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None Past Chair of the national ADRC Imaging Core Steering Committee	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None Non	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None Equipment grant from Roche Diagnostics	Grant to institution
13	Other financial or non-financial interests	None ■	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	9/29/2022
Your Name:	Ana S. Lukic]
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.	

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	ADM Diagnostics, Inc Cerveau Technologies, Inc./Enigma BioIntelligence	Salaried employee Contracted ADM Diagnostics to perform work Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None ■	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None ADM Diagnostics, Inc.	Employee stock/options
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None ■	
13	Other financial or non-financial interests	None Non	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	9/28/2022
Your Name:	Keith Alan Johnson, MD
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None Time frame: past 36 month	Click the tab key to add additional rows.
	Country			15
2	Grants or contracts from	\boxtimes	None	
	any entity (if not indicated in item			
	#1 above).	-		
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Novartis <us\$ 5,000<="" td=""> Merck <us\$ 5,000<="" td=""></us\$></us\$>
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	Cerveau, Inc. SAB, unpaid
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/28/2022
Your Name:	Pedro Rosa-Neto
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Canadian Institutes of Health Research The Fonds de recherche du Québec (FRQS) The Weston Brain Institute (WBI) Time frame: past 36 month	Institutional Institutional Click the t Institutional ab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[□] Lilly	Institutional
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees		
		Roche	Institution
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Novo Nordisk	Personal
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Alzheimer's Association INC	Institution
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

ICMJE DISCLOSURE FORM		
Date:	9/28/2022	
Your Name:	Randolph D. Andrews	
Manuscript Title:	Development, Initial Validation, and Ap [18F]MK-6240 Tau PET	oplication of a Visual Read Method for
Manuscript Number (if known): TRCI-D-22-00086R1		
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.		ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so. example, if your manuscript pertains to the acturers of antihypertensive medication, even if
	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	□ None ADM Diagnostics, Inc Cerveau Technologies, Inc./Enigma BioIntelligence Time frame: past 36 month None	Salaried employee Contracted ADM Diagnostics to perform work Click the tab key to add additional rows.
3	#1 above). Royalties or licenses	None	
	10011303		

			pecifications/Comments (e.g., if payments were nade to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None □	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None ■	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None ADM Diagnostics, Inc.	Employee stock/options
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None ■	
13	Other financial or non-financial interests	None	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	9/28/2022
Your Name:	Koen Van Laere
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if pa made to you or to your institution)			
	Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	✓ None	Click the tab key to add additional rows.	
		Time frame: past 36 month	ns	
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None Eikonizo Therapeutics CHDI BMS Cerevel Janssen Pharmaceuticals Syndesi Therapeutics Cerveau / Meilleur	Contract research through KU Leuven Tracer manufacturing contract through KU Leuven	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None ■	
6	Payment for expert testimony	GE Healthcare, blinded scan reading	Contract through KU Leuven
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None Advisory Board Cerveau Technologies	
10	Leadership or fiduciary role in other board,	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid	Vice-chair Flemish Recognition Committee for fellows in Nuclear Medicine Chair Belgian Society for Nuclear Medicine	Travel expenses paid unpaid	
11	Stock or stock options	None ■		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None Non		
13	Other financial or non-financial interests	None ■		
Plea	Please place an "X" next to the following statement to indicate your agreement:			
\boxtimes	☑ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	9/28/2022
Your Name:	Lindsay Cordes, Pharm. D.
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.			My work on the manuscript was fully funded by Cerveau Technologies. Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	StatKing Clinical Services	I was a paid employee of StatKing Clinical Services contracted by Cerveau Technologies.
Plea 🖂	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	9/28/2022
Your Name:	Larry Ward
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None Time frame: past 36 month	Click the tab key to add additional rows.
	Country			15
2	Grants or contracts from any entity (if not indicated in item #1 above).	\boxtimes	None	
		-		
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

ľ			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/28/2022
Your Name:	Claire Wilde
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None	Click the tab key to add additional rows.
			Time frame: past 36 month	is
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None ■	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

ľ			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Please place an "X" next to the following statement to indicate your agreement:				

Date:	9/28/2022	
Your Name:	Jerome A. Barakos, M.D.	
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET	
Manuscript Number (if known):	TRCI-D-22-00086R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as neede	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	9/28/2022
Your Name:	Derk D Purcell MD
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None	Click the tab key to add additional rows.
	ı		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

			cations/Comments (e.g., if payments were o you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	10/06/22	
Your Nan	ne: <u>Davangere P. Devanan</u>	<u>d, M.D</u>
Manuscri	ipt Title:	
	Development, Initial Val [18F]MK-6240 Tau PET	idation, and Application of a Visual Read Method for
Manuscri	int number (if known):	TDCI_D_22_00086D1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	NIA	
	provision of study materials,		Payments made to institution
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated	Alzheimer's Association	Payments made to institution
	in item #1 above).		
3	Royalties or licenses	xNone	

4	Consulting fees	x Acadia	Paid to Dr. Devanand (Scientific Adviser)
	J	Eisai	Paid to Dr. Devanand (Scientific Adviser)
		Jazz	Paid to Dr. Devanand (Scientific Adviser)
		BioXcel	Paid to Dr. Devanand (DSMB)
		Corium	Paid to Dr. Devanand (Scientific Adviser)
		TauRx	Paid to Dr. Devanand (Scientific Adviser)
		Biogen	Paid to Dr. Devanand (Scientific Adviser)
5	Payment or honoraria for	xNone	, ,
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x_None	
	testimony		
7	Support for attending	xNone	
	meetings and/or travel		
8	Patents planned, issued or	x None	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None in addition	Listed under item 4, Consulting fees
	in other board, society,		and a made it do in a part of the part of
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x None	
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Davangere P. Devanand, M.D.

Date:	9/28/2022
Your Name:	Jose Luchsinger
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None □	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None R01AG050440, RF1AG051556, RF1AG051556- 01S2, R01AG055299, K24AG045334	NIH grants funding data collection for this manuscript
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Merck	I am consultant to Merck for content unrelated to this manuscript
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	□ None Merck	Attending the EASD 2022 meeting in Stockholm, Sweden
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None I am the chair of a DSMB for an NIH funded clinical trial of a light intervention in persons with dementia	Unrelated to this manuscript
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None Vice Chair of the board of ARC Ft. Washington Senior center in NYC	Unpaid

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None ■	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	□ None Wolters Kluwer	I receive a stipend as Editor in Chief of the journal Alzheimer's disease and Associated Disorders
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

ICMJE DISCLOSURE FORM				
Date:	9/28/2022	9/28/2022		
Your Name:	Cyrille Sur			
Manuscript Title:	Development, Initial Validation, and A [18F]MK-6240 Tau PET	pplication of a Visual Read Method for		
Manuscript Number (if kno	own): TRCI-D-22-00086R1			
content of your manuscript affected by the content of indicate a bias. If you are in the author's relationships/epidemiology of hypertense that medication is not menually in item #1 below, report all	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			
	ame all entities with whom you have this elationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning	of the work		

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Men	None ck Sharp and Dohme full time employee	Click the tab key to add additional rows.
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None Hold shares of Merck Sharp and Dohme as part of my employment benefits	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None ■	
13	Other financial or non-financial interests	None ■	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	9/28/2022
Your Name:	Julie C, Price, PhD
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Institutes of Health R01AG050436 National Institutes of Health R01AG052414 National Institutes of Health R21AG060293	Research grant. (PI, Price) Research grant (PI: Vasdev/Price) Research grant (PI: Becker)
		Time frame: past 36 month	ns
2	Grants or contracts from	□ None	
	any entity (if not indicated in item	National Institutes of Health R01AG062559	
			Research Grant (PI, Jacobs)
		National Institutes of Health R61DA048485	Research Grant (PI, Wey)
	#1 above).	National Institutes of Health R61DA048485 National Institutes of Health UH2AR076741	Research Grant (PI, Wey) Research Grant (PI, Wey)
		National Institutes of Health R61DA048485 National Institutes of Health UH2AR076741 National Institutes of Health P01AG036694	Research Grant (PI, Wey) Research Grant (PI, Wey) Research Grant (PI, Johnson/Sperling)
		National Institutes of Health R61DA048485 National Institutes of Health UH2AR076741 National Institutes of Health P01AG036694 Michael J. Fox Foundation 18768	Research Grant (PI, Wey) Research Grant (PI, Wey) Research Grant (PI, Johnson/Sperling) Research Grant (PI, Wang)
		National Institutes of Health R61DA048485 National Institutes of Health UH2AR076741 National Institutes of Health P01AG036694 Michael J. Fox Foundation 18768 National Institutes of Health R01DK112700	Research Grant (PI, Wey) Research Grant (PI, Wey) Research Grant (PI, Johnson/Sperling) Research Grant (PI, Wang) Research Grant (PI, Delaney/Price)
		National Institutes of Health R61DA048485 National Institutes of Health UH2AR076741 National Institutes of Health P01AG036694 Michael J. Fox Foundation 18768 National Institutes of Health R01DK112700 National Institutes of Health U01EB029826	Research Grant (PI, Wey) Research Grant (PI, Wey) Research Grant (PI, Johnson/Sperling) Research Grant (PI, Wang) Research Grant (PI, Delaney/Price) Research Grant (PI, Catana)
		National Institutes of Health R61DA048485 National Institutes of Health UH2AR076741 National Institutes of Health P01AG036694 Michael J. Fox Foundation 18768 National Institutes of Health R01DK112700	Research Grant (PI, Wey) Research Grant (PI, Wey) Research Grant (PI, Johnson/Sperling) Research Grant (PI, Wang) Research Grant (PI, Delaney/Price) Research Grant (PI, Catana) Research Grant (PI, Handen; Site PI: Lai)
		National Institutes of Health R61DA048485 National Institutes of Health UH2AR076741 National Institutes of Health P01AG036694 Michael J. Fox Foundation 18768 National Institutes of Health R01DK112700 National Institutes of Health U01EB029826 National Institutes of Health U01AG051412	Research Grant (PI, Wey) Research Grant (PI, Wey) Research Grant (PI, Johnson/Sperling) Research Grant (PI, Wang) Research Grant (PI, Delaney/Price) Research Grant (PI, Catana)
		National Institutes of Health R61DA048485 National Institutes of Health UH2AR076741 National Institutes of Health P01AG036694 Michael J. Fox Foundation 18768 National Institutes of Health R01DK112700 National Institutes of Health U01EB029826 National Institutes of Health U01AG051412 National Institutes of Health T32AG066592	Research Grant (PI, Wey) Research Grant (PI, Wey) Research Grant (PI, Johnson/Sperling) Research Grant (PI, Wang) Research Grant (PI, Delaney/Price) Research Grant (PI, Catana) Research Grant (PI, Handen; Site PI: Lai) Research Grant (PI, Price)
		National Institutes of Health R61DA048485 National Institutes of Health UH2AR076741 National Institutes of Health P01AG036694 Michael J. Fox Foundation 18768 National Institutes of Health R01DK112700 National Institutes of Health U01EB029826 National Institutes of Health U01AG051412 National Institutes of Health T32AG066592 National Institutes of Health P01AT009965	Research Grant (PI, Wey) Research Grant (PI, Wey) Research Grant (PI, Johnson/Sperling) Research Grant (PI, Wang) Research Grant (PI, Delaney/Price) Research Grant (PI, Catana) Research Grant (PI, Handen; Site PI: Lai) Research Grant (PI, Price) Research Grant (PI, Napatow/Rosen)

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		National Institutes of Health U19 AG 068054 National Institutes of Health R56AG070827 National Institutes of Health R01AG076153 National Institutes of Health R61NS126029 National Institutes of Health R33DA048485 National Institutes of Health R01AG078250	Research Grant (PI, Wey) Research Grant (PI, Gomperts) Research Grant (PI, El Fakhri) Research Grant (PI, Shen) Research Grant (PI, Wey) Research Grant (PI, Gong)
3	Royalties or licenses	None ■	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Univ Southern California Neuroscience Program AdventHealth Translational Research Institute	Distinguished Speaker Lecture, 2021 Seminar Lecture, 2022
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	□ None 2022 Brain & BrainPET meeting (ISBFM) 2020 Society of Nuclear Medicine Molecular Imaging	Tau Symposium speaker Mid-winter Mtg, Lecturer
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Monitoring Board or Advisory Board	Univ. Pennsylvania - External Liaison Committee	U19NS110456 (PI Mach)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	International Society Blood Flow Metabolism NIH Center for Scientific Review Neuroreceptor Mapping Meeting Human Amyloid Imaging Conference Alzheimer's Association	Publication Committee Advisory Council to Director, 2017-2021 Scientific Advisory Committee Program Committee Appropriate Use Criteria Working Group
11	Stock or stock options	None Non	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None ■	
13	Other financial or non-financial interests	None ■	
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	9/28/2022
Your Name:	Adam M. Brickman
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None funding RF1AG054070, R01AG054070, AG058067	Click the tab key to add additional rows.
		Time frame: past 36 month	ns .
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None INS Regeneron scientific advising Cognition Therapeutics scientific advising H. Hoffmann La Roche advisory board	Self Self self
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	□ None Flomenhaft Law Firm consultant	self
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None Albert Einstein College of Medicine CogState	Self Self
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None INS Dementia SIG	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/28/2022
Your Name:	William E. Klunk, MD, PhD
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

_			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIA	None P01 AG025204 Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

			specifications/Comments (e.g., if payments were nade to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None □	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None ■	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	9/28/2022
Your Name:	Adam L. Boxer, MD, PhD
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ None University of California Cures AD Program	Click the tab key to add additional rows.
		Time frame: past 36 months	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None NIH, Bluefield Project, Rainwater Charitable Foundation Biogen, Eisai, Regeneron	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Alector, Arvinas, Arkuda, AGTC, Life Edit, GSK, Humana, Aviado, Oscotec, Roche, Transposon, Wave	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	American Academy of Neurology	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Alector, Arvinas, Arkuda, True Binding	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	None	
r 1	Please place an "X" next to the following statement to indicate your agreement:		
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	9/28/2022
Your Name:	Sulantha Mathotaarachchi
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

_			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None Time frame: past 36 month	Click the tab key to add additional rows.
	Country			15
2	Grants or contracts from any entity (if not indicated in item #1 above).	\boxtimes	None	
		-		
3	Royalties or licenses		None	

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None ■	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: Certify that have answered every question and have not altered the wording of any of the questions on this form.			

Date:	9/28/2022
Your Name:	Patrick Lao
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	K99	None AG065506	Click the tab key to add additional rows.
			Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

li.			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Please place an "X" next to the following statement to indicate your agreement:				

Date:	9/28/2022
Your Name:	Jeffrey L. Evelhoch
Manuscript Title:	Development, Initial Validation, and Application of a Visual Read Method for [18F]MK-6240 Tau PET
Manuscript Number (if known):	TRCI-D-22-00086R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None	Click the tab key to add additional rows.	
			Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	Me	None rck & Co., Inc.	Employee (retired)	
3	Royalties or licenses		None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
4	Consulting fees	□ None		
		Cerveau Technologies, Inc.	Paid to me	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Non		
6	Payment for expert testimony	None ■		
7	Support for attending meetings and/or travel	Cerveau Technologies, Inc.	Attending meetings and travel	
8	Patents planned, issued or pending	None Non		
9	Participation on a Data Safety Monitoring Board or Advisory Board	Cerveau Technologies, Inc.	Past member of Scientific Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	□ None Merck & Co., Inc.	Stock, options		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None ■			
13	Other financial or non-financial interests	None			
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					